Mesoblast shares fall on trial’s mixed results with heart injection treatment

Mesoblast’s six-year study into using a cell stem injection to prevent heart failure failed to meet clinical endpoints Rexlemestrocel-L appeared … Read More

The post Mesoblast shares fall on trial’s mixed results with heart injection treatment appeared first on Stockhead.

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *